<DOC>
	<DOCNO>NCT01234350</DOCNO>
	<brief_summary>This study large observational study set-up observe long-term treatment Firmagon ( hormone regulator ) compare another treatment effect specific condition cardiovascular event , change bone density , change blood sugar level liver enzyme level patient prostate cancer . Patients treat accord routine clinical care dictate study . As study observational nature , study collect specific data relate 3 specific event . Patients agree study followed-up 5 year . Patient data collect every 3 month first 2 year every 6 month last 3 yr .</brief_summary>
	<brief_title>Post Authorisation Safety Study ( PASS ) Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Diagnosed prostate cancer indicate androgen deprivation therapy ( ADT ) Decision make prescribe ADT prior enrolment Willing able provide write informed consent Participation interventional clinical study treatment followup mandate Treatment GnRH receptor antagonist Firmagon Had previous currently hormonal management prostate cancer , except patient undergone therapy curative intention neoadjuvant/adjuvant therapy allow maximum 6 month . Treatment terminate least 6 month prior baseline .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>